Eli Lilly and Company successfully secured the transfer of the domain buttiemmounjaro.com from respondent Mai Kim My Hanh. The panel found that the respondent used the domain to offer prescription medication without authorization and in bad faith, violating the complainant’s trademark rights.
Case Snapshot
| Case Number | D2026-3567 |
|---|---|
| Complainant | Eli Lilly and Company |
| Respondent | Mai Kim My Hanh |
| Disputed Domain | buttiemmounjaro.com |
| Threat Tactic | Fake Stores |
| Decision Date | 2026-09-03 |
| Panelist | Wilson Pinheiro Jabur |
| Outcome | Transfer |
| Official Source | https://www.wipo.int/amc/en/domains/search/text.jsp?case=D2026-3567 |
Facing Unauthorized Domain Registrations or Brand Abuse?
Our domain dispute attorneys represent trademark owners and businesses worldwide before WIPO, Forum (NAF), and CAC. Explore our Domain Name Disputes and Enforcement & Takedowns services, or request a free case evaluation.
Request Case EvaluationBusiness and Security Risks of Pharmaceutical Trademark Impersonation
The registration and active use of domains like ‘buttiemmounjaro.com’ pose severe commercial and safety risks by facilitating the unauthorized distribution of prescription-only pharmaceutical products. By combining the MOUNJARO trademark with descriptive local terms such as ‘buttiem’ (Vietnamese for ‘injection pen’), the respondent created a targeted storefront designed to capture consumer traffic seeking legitimate medical products. This tactic exploits brand authority to bypass standard pharmaceutical supply chains, offering unregulated, potentially counterfeit, or grey-market medications without requiring a valid prescription. Such operations directly undermine the integrity of the Complainant’s distribution channels and pose significant health risks to consumers who may believe they are purchasing authentic, FDA-approved treatments.
Beyond the immediate threat of fraudulent product sales, these tactics damage consumer trust and corporate reputation. The respondent’s failure to disclose a lack of affiliation with Eli Lilly constitutes a deceptive practice aimed at creating false credibility. Even when such domains transition to inactive or passive holding status, the initial impact remains: the brand’s reputation is linked to unauthorized transactions, and traffic is diverted away from official, verified channels. For pharmaceutical brand owners, these incidents highlight the necessity of aggressive monitoring and rapid enforcement to prevent the long-term erosion of trademark equity and to minimize potential liability stemming from the health risks associated with unregulated, off-label drug procurement.
Legal Reasoning: Analyzing Confusing Similarity and Bad Faith in Pharmaceutical Domain Disputes
The panel determined that the disputed domain name, ‘buttiemmounjaro.com’, is confusingly similar to Eli Lilly’s MOUNJARO trademark. The inclusion of ‘buttiem’, the Vietnamese term for ‘injection pen’, failed to negate the likelihood of confusion, as the domain effectively incorporates the highly distinctive trademark to create a deceptive association. This finding reinforces the UDRP precedent that appending descriptive or local-language terms to a well-known brand does not avoid a finding of confusing similarity, particularly when the resulting domain name suggests an affiliation with the mark owner that does not exist.
The respondent lacked any rights or legitimate interests in the disputed domain. The panel observed that the respondent was not commonly known by the domain name and was not making a legitimate noncommercial or fair use of the property. Instead, the domain was utilized to offer prescription-only products without requiring a valid prescription, a business model that purposefully exploits the brand for commercial gain while potentially harming consumers. The respondent’s failure to disclose the lack of any official relationship with Eli Lilly further solidified the conclusion that their activities were purely for the purpose of misleading internet users.
The panel’s finding of bad faith was centered on the respondent’s intentional use of the domain to divert traffic for commercial profit through the unauthorized sale of pharmaceuticals. By mimicking the complainant’s branding, the respondent created a clear likelihood of confusion. The panel noted that even if the domain is currently inactive, the prior use of the site to advertise prescription drugs—and the failure to provide any disclaimer of affiliation—established bad faith under the UDRP. This outcome demonstrates that panels will look beyond the current status of a domain to the prior pattern of use to verify that registration was made with the express intent of exploiting the complainant’s trademark rights.
This decision highlights that brand owners can successfully leverage UDRP proceedings even when respondents employ language-specific descriptors to obscure infringement. The consistency of this panel’s reasoning with previous pharmaceutical disputes, such as Case No. D2023-4568, serves to protect global brands from unauthorized vendors who attempt to bypass regulatory hurdles for prescription drugs. For IP professionals, the case affirms that evidence of past infringing content is sufficient to support a transfer, ensuring that the burden remains on the respondent to justify their use of the domain through legitimate, non-misleading activities.
Strategic Enforcement Against Localized Pharmaceutical Infringement
Eli Lilly’s successful strategy relied on effectively framing the disputed domain name, ‘buttiemmounjaro.com’, as a direct infringement despite the inclusion of the Vietnamese term for ‘injection pen’. By demonstrating that the addition of descriptive local-language terms did not dilute the distinctiveness of the MOUNJARO trademark, the complainant established a clear case for confusing similarity. This highlights the importance of comprehensive global trademark portfolios, as documenting foreign-language equivalents and local market context provides the necessary evidence to neutralize arguments that descriptive suffixes create a unique or legitimate identity for the registrant.
The complainant’s persuasive evidence package focused on the respondent’s failure to disclose a lack of affiliation, coupled with the illicit offering of prescription-only drugs. By citing established UDRP precedents regarding unauthorized pharmaceutical sales, the complainant demonstrated that the respondent’s activities were not merely trademark misuse, but a calculated commercial attempt to exploit the brand’s reputation. Even when the respondent transitioned the site to passive holding, the evidentiary record of past infringing content proved sufficient to secure a transfer. This approach confirms that brand owners can effectively combat evasive tactics, such as the temporary disabling of a site, by maintaining rigorous documentation of previous malicious use.
Practical Recommendations
- Monitor for domain registrations that combine core brand trademarks with descriptive local-language terms, such as ‘injection pen’ (buttiem), which are commonly used to target regional prescription markets.
- Perform screenshotting and DNS logging of infringing sites immediately upon discovery, as respondents frequently toggle sites to ‘passive’ status to evade UDRP findings during the dispute process.
- Include explicit evidence in filings—such as archives or screenshots—that demonstrates the failure of the respondent to disclose their lack of affiliation with the brand, which is a key indicator of bad faith.
- Reference established UDRP pharmaceutical precedents in your complaint to emphasize the specific risk posed by the unauthorized sale of prescription-only medication, which strengthens the panel’s bad-faith assessment.
- Proactively initiate UDRP proceedings even if a domain appears inactive, as panels consistently view the past use of a site to offer unauthorized prescription drugs as sufficient evidence to justify a transfer.
Frequently Asked Questions (FAQ)
Why did the panel consider ‘buttiemmounjaro.com’ to be confusingly similar to the MOUNJARO trademark?
The panel found that the disputed domain combined Eli Lilly’s highly distinctive MOUNJARO trademark with the Vietnamese term ‘buttiem’ (meaning ‘injection pen’). Because the trademark remained the dominant component, adding a descriptive term in a local language did not mitigate the risk of consumer confusion.
What evidence established the respondent’s bad faith in this case?
Bad faith was proven by the respondent’s use of the domain to offer prescription-only MOUNJARO products without requiring a prescription and without disclosing that there was no affiliation with Eli Lilly. This pattern of behavior is a clear attempt to attract users for commercial gain by exploiting the complainant’s reputation.
Does the fact that the domain is currently inactive protect the registrant from a UDRP transfer?
No. Even though the domain was inactive at the time of the decision, the panel accounted for its prior use in hosting an infringing website. Past evidence of offering unauthorized products under the MOUNJARO mark is sufficient to support a finding of bad faith and a transfer of the domain.
How can brand owners combat the use of local-language terms combined with their trademarks?
Brand owners should monitor for variations that combine their mark with descriptive local terms, such as ‘buttiem’ (injection pen). As demonstrated here, evidence of the domain being used to bypass legitimate medical safety requirements, like prescription verification, provides a strong basis for UDRP success regardless of the registrant’s attempt to ‘hide’ the domain through passive holding.
Found a fake shop using your brand?
Protect your customers and reputation. Learn how to identify and initiate UDRP proceedings against unauthorized pharmaceutical sites mimicking your brand and selling illicit products.
This case note is for informational purposes only and is not legal advice.
